8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
Mar 17, 2026·SEC
ArriVent BioPharma, Inc. Common Stock(AVBP)Earnings, Financials & Key Ratios
AVBP•NASDAQ
$34.18
Price updated Jul 7, 2026
AboutArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Show more
- Revenue$0
- EBITDA-$178M-120.6%
- Net Income-$166M-106.6%
- EPS (Diluted)-4.32-68.8%
- ROE-58.88%-49.6%
AVBP Price & Volume
ArriVent BioPharma, Inc. Common Stock (AVBP) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Cash Reserve Growth
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
Key Thesis Takeaways
- ArriVent BioPharma is currently in a high-stakes, capital-intensive phase as it prioritizes the FURVENT Phase 3 clinical trial, which has driven quarterly R&D expenditures to $37.6 million as of 2026Q1.
- The company's reliance on external financing is underscored by a rapidly depleting cash position that fell from $317.4 million in 2024Q1 to $62.1 million in 2026Q1.
- Investors should monitor the binary risk associated with clinical milestones, as the current operating loss of $46.1 million per quarter suggests a precarious runway without additional capital infusion.
Verdict Logic
the company's cash reserves of $62.1 million as of 2026Q1 are insufficient to cover the current quarterly net loss of $43.3 million, indicating a high probability of near-term shareholder dilution.
AVBP Growth Metrics
ArriVent BioPharma, Inc. Common Stock (AVBP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-13.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM6.37%
Return on Capital
10 Years-42.01%
5 Years-42.01%
3 Years-51.57%
Last Year-62.86%
AVBP Recent Earnings
ArriVent BioPharma, Inc. Common Stock (AVBP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (50%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.96-9.1%
$0.88
Rev
—
—
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.78+10.3%
$0.87
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.83-6.4%
$0.78
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.90-28.6%
$0.70
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.96vs $0.88-9.1% | — |
| Q2 2026 | Mar 5, 2026 | $0.78vs $0.87+10.3% | — |
| Q4 2025 | Nov 10, 2025 | $0.83vs $0.78-6.4% | — |
| Q3 2025 | Aug 11, 2025 | $0.90vs $0.70-28.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for ArriVent BioPharma, Inc. Common Stock (AVBP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $34.18 | $1.59B | -7.91 | — | — | -58.88% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $4.75 | $192.85M | 3.89 | 36.55% | -19.55% | -3.39% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $123.77 | $9.1B | -21.16 | — | — | -42.78% | — | |
| $60.89 | $2.62B | -38.30 | 146.71% | -9.02% | -14.19% | — |
Compare AVBP vs Peers
ArriVent BioPharma, Inc. Common Stock (AVBP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AVBP SEC Filings & Documents
ArriVent BioPharma, Inc. Common Stock (AVBP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when AVBP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AVBP Frequently Asked Questions
ArriVent BioPharma, Inc. Common Stock (AVBP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is AVBP profitable?
ArriVent BioPharma, Inc. Common Stock (AVBP) reported a net loss of $145.2M for fiscal year 2025.
Dividend & Returns
What is AVBP's return on equity?
ArriVent BioPharma, Inc. Common Stock (AVBP) has a return on equity (ROE) of -58.9%. Negative ROE indicates the company is unprofitable.
What is ArriVent BioPharma, Inc. Common Stock's free cash flow?
ArriVent BioPharma, Inc. Common Stock (AVBP) had negative free cash flow of $134.5M in fiscal year 2025, likely due to heavy capital investments.